Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2020
Event: Regulation FD Disclosure regarding a government contract amendment and option exercise for the COVID-19 vaccine candidate mRNA-1273.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain audited financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the terms of a supply agreement amendment.
Material Changes
- Contract Expansion: The U.S. government exercised an option to purchase an additional 100 million doses of the mRNA-1273 vaccine candidate under the existing U.S. Supply Agreement dated August 11, 2020.
- Timing Amendment: The parties entered into an amendment to the U.S. Supply Agreement permitting the U.S. government to exercise this option prior to the granting of an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the option and the amendment to the supply agreement but does not provide forward-looking financial guidance or revenue projections associated with this specific order in this document.
Risks and Contingencies: The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth. The ability to fulfill the order remains contingent on regulatory approvals (EUA) and manufacturing capabilities, though the amendment specifically allows the option exercise to precede the EUA.
Investor Verification Checklist
- Verify the total cumulative number of doses under the U.S. Supply Agreement following this 100 million dose addition.
- Confirm the specific pricing terms per dose for this additional tranche, which are not detailed in this 8-K.
- Review the full text of the amendment (Exhibit 99.1) for any new delivery schedules or penalty clauses associated with pre-EUA exercise.
- Monitor subsequent filings for the actual revenue recognition timeline once the EUA is granted and doses are delivered.
